window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

target engagement

  • Uncategorised

    Selvita licenses Medicines Discovery Catapult’s target engagement technology

    Selvita has become the first contract research organisation (CRO) to [...]

    May 29, 2025
  • Drug Development

    Landmark BioVentures and G.CLIPS Biotech join forces to tackle drug target engagement bottlenecks

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top